Lymphoma News

FDA Grants Accelerated Approval to Brukinsa for Mantle Cell Lymphoma (December 5, 2019)

Continued approval may be contingent upon verification of clinical benefit in a confirmatory trial The Food and Drug Administration (FDA) has granted accelerated approval to Brukinsa (zanubrutinib; BeiGene USA) for the treatment of adult patients with... Continue Reading

FDA approves Calquence Treatment for Treatment of Mantle Cell Lymphoma (November 6, 2017)

The U.S. Food and Drug Administration has granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy.  Mantle cell lymphoma is a particularly aggressive... Continue Reading